iNtODEWORLD | The World’s First Clinical Trial with Endolysin-based Bio-drug
16143
page,page-id-16143,page-template,page-template-full_width,page-template-full_width-php,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,qode_grid_1300,qode-theme-ver-11.0,qode-theme-bridge,wpb-js-composer js-comp-ver-5.1.1,vc_responsive

iNtRON’s Development Programs

Targeting bacterial infections

DURING THE DEVELOPMENT OF THE ENDOLYSIN BIO-DRUGS WHICH TARGETS GRAM POSITIVE BACTERIA, OUR GOALS ARE AS FOLLOWS:
  • Methicillin-resistant Staphylococcus aureus(MRSA) infection treatment
  • Vancomycin-resistant Staphylococcus aureus(VRSA) infection treatment
  • Vancomycin-resistant Enterococcus(VRE) infection treatment
  • Penicillin-resistant Streptococcus pneumoniae(PRSP) infection treatment
gaserh

N-Rephasin® SAL200 (SAL200): FIRST-IN-HUMAN CLINICAL TRIAL

iNtRON HAS A NOVEL BIO-DRUG (SAL200) WHICH IS NOW IN A PHASE II IN-HUMAN CLINICAL TRIAL.

 

  • World’s first human clinical trial targeting MRSA infections is now ongoing.
  • The Phase I clinical trial proved safe in humans and the Phase II clinical trial has been initiated.

ADVANTAGES OF ENDOLYSIN BIO-DRUGS

bsetn3

Advantages of Endolysin Bio-drugs

  • A solution to antibiotic resistance and antibiotic tolerance
  • Work effectively against biofilms and are able to provide antibacterial activity to persister cells
  • Safe for animals and plants due to Endolysin bio-drugs are only effective against targeted bacteria
  • Have a fundamentally different Mode-of-Action which allows for antibacterial activity against bacterial strains resistant to conventional antibiotics including superbugs
  • Able to confer fast antibacterial activity through direct hydrolysis of bacterial cell walls, demonstrating a characteristic of these powerful bactericidal antibiotics
  • Very low possibility of resistance developing as the point of action is at the essential linkages in the bacteria
iNtODEWORLD, Inc is the US subsidiary of iNtRON Biotechnology, Inc.